Collegium Pharma (COLL) Stock Price, Quote & News

Company Profile

Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. The company's portfolio includes Jornay PM, a central nervous system stimulant prescription medicine that contains methylphenidate HCl for the treatment of attention deficit hyperactivity disorder; Belbuca, a buccal film that contains buprenorphine for severe and persistent pain that requires an extended treatment period; Xtampza ER, an abuse-dete...

Industry: Drug Manufacturers - Specialty & Generic

Sector: Healthcare

Phone: 781 713 3699

Website: www.collegiumpharma.com

Address:

100 Technology Center Drive, Suite 300, Stoughton, United States

ZacksResearch Feb. 19 at 4:34 PM

$COLL earnings incoming — is this the quarter bulls have been waiting for? 👀 Strong demand for Jornay PM and higher pain portfolio sales are fueling expectations heading into the Feb. 26 Q4 report. Momentum in core products is setting the tone — now it’s about execution. Will the numbers back up the optimism? Discover what’s in the cards 👉 https://www.zacks.com/stock/news/2872151/collegium-pharmaceutical-to-report-q4-earnings-whats-in-the-cards?cid=sm-stocktwits-2-2872151-teaser-34265&ADID=SYND_STOCKTWITS_TWEET_2_2872151_TEASER_34265

0 · Reply

ZacksResearch Feb. 19 at 3:34 PM

$COLL Q4 earnings preview: Can Jornay PM drive another revenue boost? 📈 Collegium's Q4 revenues are expected to be fueled by strong performance of Jornay PM and a likely increase in its pain portfolio sales. However, with an Earnings ESP of -2.43% and a Zacks Rank #3, an earnings beat may not be on the cards this time. Discover the full outlook here 👉 https://www.zacks.com/stock/news/2872151/collegium-pharmaceutical-to-report-q4-earnings-whats-in-the-cards?cid=sm-stocktwits-2-2872151-body-34264&ADID=SYND_STOCKTWITS_TWEET_2_2872151_BODY_34264

0 · Reply

EmotionlessMarket Feb. 18 at 3:29 PM

$COLL Collegium Pharmaceutical is a specialty pharma company with stable opioid-related cash flows. Growth depends on portfolio expansion and disciplined capital allocation. Regulatory risk remains a long-term overhang.

0 · Reply

Estimize Feb. 18 at 2:18 PM

Wall St is expecting 2.14 EPS for $COLL Q4 [Reporting 02/26 BMO] http://www.estimize.com/intro/coll?chart=historical&metric_name=eps&utm_co

0 · Reply

jewell69 Feb. 13 at 3:07 PM

$COLL placed a sell 300 on a mkt on close order 2/13/26 now at 10;06 am est the b a is 45.51 x .60 last trade 45.53 high so far for the day 45.84; 45.28 is the low so for the day as of 10:06 am est

1 · Reply

jewell69 Feb. 11 at 7:36 PM

$COLL 2/10 B 300 44.56 2/11 B 300 44.69 2/11 S 300 45.39 ALL done in an ira. I still own 300 "living in luxury on the pain and suffering of others" they sell non-addictive opiods.

0 · Reply

jewell69 Feb. 11 at 5:36 PM

$COLL doubling down b yesterdday 2/10 300 b 300 more on bad down day -4.58% on ?? good ?? news ?? Truist Adjusts Price Target on Collegium Pharmaceutical to $58 From $55, Maintains Buy Rating

1 · Reply

jewell69 Feb. 10 at 4:11 PM

b $CPS 34.85 stifel focus list b $COLL 46.05 trying 2 add on to $XLY 118.40 at 11 am est on 2/10 119.07 x .08 previous buy 2/6 117.56 and .70 in variable annuity went from cash to $XLK clone. I will get 2/10 closing price. Money came from $IYZ clone, ugh !

0 · Reply

jewell69 Feb. 10 at 1:34 AM

IN LUXURY ON THE PAIN AND SUFFERING OF OTHERS ! they sell non-addictive opiods. $COLL the "post-modern high" close 12/29 49.52 2/9/26 close 46.28 (-2.79% for today) 11/5/25 close ONLY 35.09; b4 blowout earns 2.25 vs 2.044 estimated this looks better than $BKNG to say the least tip ranks 4 out of 4 say buy. pts of 58 cut to 56 ugh! 46 raised to 60 55 48 raised to 56 me? 11/6/25 s 51 at 40.05 other acct. 1/9/26 day trade b and sell b just 40 shares 45.29 s 40 at 46.04

0 · Reply

BillionerOfKing Feb. 5 at 5:38 AM

$COLL Current Stock Price: $48.19 Contracts to trade: $50.0 COLL Feb 20 2026 Call Entry: $1.12 Exit: $1.84 ROI: 64% Hold ~27 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts

0 · Reply

Collegium Pharmaceutical: Buying The Projected Growth For 2026

Jan 15, 2026, 8:00 AM EST - 5 weeks ago

Collegium to Present Four Real-World Data Posters at APSARD 2026 Annual Conference

Jan 8, 2026, 8:00 AM EST - 6 weeks ago

Collegium Provides 2026 Financial Guidance and Business Update

Dec 30, 2025, 8:00 AM EST - 7 weeks ago

Collegium Announces the Closing of $980 Million Syndicated Credit Facility

Nov 12, 2025, 8:00 AM EST - 3 months ago

Collegium to Participate in Upcoming Investor Conferences

Nov 10, 2025, 4:27 PM EST - 3 months ago

Collegium Pharmaceutical: Another Solid Quarter

Nov 6, 2025, 10:06 PM EST - 3 months ago

Collegium Pharmaceutical, Inc. (COLL) Q3 2025 Earnings Call Transcript

Nov 6, 2025, 7:30 AM EST - 3 months ago

Collegium Reports Third Quarter 2025 Financial Results; Raises 2025 Guidance

Oct 30, 2025, 5:15 PM EDT - 4 months ago

Knight Therapeutics Announces Launch of JORNAY PM™ in Canada

Oct 23, 2025, 8:00 AM EDT - 4 months ago

Collegium to Report Third Quarter 2025 Financial Results on November 6, 2025

Oct 22, 2025, 8:00 AM EDT - 4 months ago

Collegium Announces Poster Presentations at the American Academy of Child & Adolescent Psychiatry and Neuroscience Education Institute Conferences

Oct 13, 2025, 8:00 AM EDT - 4 months ago

Collegium to Celebrate 10-Year Anniversary with Nasdaq Opening Bell Ringing

Sep 8, 2025, 5:03 PM EDT - 6 months ago

Collegium Pharmaceutical, Inc. (COLL) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript

Aug 25, 2025, 8:00 AM EDT - 6 months ago

Collegium to Present Nine Real-World Data Posters at PAINWeek 2025 Annual Meeting

Aug 7, 2025, 2:00 PM EDT - 7 months ago

Collegium Pharmaceutical, Inc. (COLL) Q2 2025 Earnings Call Transcript

Aug 7, 2025, 7:30 AM EDT - 7 months ago

Collegium Reports Second Quarter 2025 Financial Results; Raises 2025 Outlook

Jul 24, 2025, 8:00 AM EDT - 7 months ago

Collegium to Report Second Quarter 2025 Financial Results on August 7, 2025

Jul 7, 2025, 8:00 AM EDT - 8 months ago

Collegium Announces $150 Million Share Repurchase Program

Jun 30, 2025, 2:53 PM EDT - 8 months ago

Collegium Pharmaceutical: Stock Deserves A "Buy" Call On Undervaluation Of ADHD Drug

May 12, 2025, 8:05 AM EDT - 10 months ago

Collegium Announces $25 Million Accelerated Share Repurchase Program

May 9, 2025, 2:04 AM EDT - 10 months ago

Collegium Pharmaceutical, Inc. (COLL) Q1 2025 Earnings Call Transcript

May 8, 2025, 4:01 PM EDT - 10 months ago

Collegium Reports First Quarter 2025 Financial Results and Highlights Recent Company Progress

Apr 24, 2025, 8:00 AM EDT - 10 months ago

Collegium to Report First Quarter 2025 Financial Results on May 8, 2025

Apr 1, 2025, 8:00 AM EDT - 11 months ago

Collegium to Participate in 24th Annual Needham Virtual Healthcare Conference

Mar 27, 2025, 8:00 AM EDT - 11 months ago

Collegium to Present Real-World Data at PainConnect 2025, the American Academy of Pain Medicine's Annual Meeting

Mar 17, 2025, 7:00 AM EDT - 1 year ago

Collegium Announces Updates to its Board of Directors and Executive Leadership Team

Mar 10, 2025, 6:57 PM EDT - 1 year ago

Collegium Announces Poster Presentations at the 2025 National Association of Pediatric Nurse Practitioners National Conference on Pediatric Health Care

Mar 9, 2025, 4:07 AM EDT - 1 year ago

Collegium Pharmaceutical's Shareholders Might Be In For A Pain-Free 2025

Feb 27, 2025, 9:03 PM EST - 1 year ago

Collegium Pharmaceutical, Inc. (COLL) Q4 2024 Earnings Call Transcript

Feb 27, 2025, 4:01 PM EST - 1 year ago

Collegium Reports Record Fourth Quarter and Full-Year 2024 Financial Results

Feb 13, 2025, 8:00 AM EST - 1 year ago

Collegium to Report Fourth Quarter and Full-Year 2024 Financial Results on February 27, 2025

Jan 8, 2025, 8:00 AM EST - 1 year ago

Collegium Provides 2025 Financial Guidance and Business Update

Nov 26, 2024, 8:00 AM EST - 1 year ago

Collegium Pharmaceutical: Strong Growth With Pain Management And ADHD Expansion

Nov 14, 2024, 4:30 PM EST - 1 year ago

Knight Therapeutics Announces Health Canada Approval for JORNAY PM™ to Treat Attention-Deficit Hyperactivity Disorder (ADHD)

Nov 8, 2024, 12:30 AM EST - 1 year ago

Collegium Pharmaceutical, Inc. (COLL) Q3 2024 Earnings Call Transcript

Nov 7, 2024, 4:02 PM EST - 1 year ago

Collegium Reports Record Third Quarter 2024 Financial Results

Aug 30, 2024, 8:00 AM EDT - 1 year ago

Collegium to Participate in H.C. Wainwright 26th Annual Global Investment Conference

Aug 8, 2024, 9:30 PM EDT - 1 year ago

Collegium Pharmaceutical, Inc. (COLL) Q2 2024 Earnings Call Transcript

Aug 8, 2024, 4:01 PM EDT - 1 year ago

Collegium Reports Second Quarter 2024 Financial Results

Jul 29, 2024, 6:00 AM EDT - 1 year ago

Collegium to Acquire Ironshore Therapeutics, Expanding into Neurology

May 29, 2024, 8:00 AM EDT - 1 year ago

Collegium to Participate in Jefferies Global Healthcare Conference

May 13, 2024, 8:00 AM EDT - 1 year ago

Collegium Announces $35 Million Accelerated Share Repurchase Program

May 9, 2024, 7:32 PM EDT - 1 year ago

Collegium Pharmaceutical, Inc. (COLL) Q1 2024 Earnings Call Transcript

May 9, 2024, 4:02 PM EDT - 1 year ago

Collegium Reports First Quarter 2024 Financial Results

Apr 25, 2024, 8:00 AM EDT - 1 year ago

Collegium to Report First Quarter 2024 Financial Results on May 9, 2024

Apr 11, 2024, 8:00 AM EDT - 2 years ago

Collegium Pharmaceutical, Inc. Announces Redemption of Outstanding 2.625% Convertible Senior Notes Due 2026

Mar 12, 2024, 5:00 AM EDT - 2 years ago

Top 10 Small-Cap Stocks (SA Quant)

ANIP APOG BLBD GCT PLMR RAMP RDCM

Feb 22, 2024, 9:52 PM EST - 2 years ago

Collegium Pharmaceutical's (COLL) Q4 2023 Earnings Call Transcript

Feb 22, 2024, 4:09 PM EST - 2 years ago

Collegium Reports Record Fourth Quarter and Full-Year 2023 Financial Results

Feb 8, 2024, 8:00 AM EST - 2 years ago

Collegium to Report Fourth Quarter and Full-Year 2023 Financial Results on February 22, 2024

ZacksResearch Feb. 19 at 4:34 PM

0 · Reply

ZacksResearch Feb. 19 at 3:34 PM

0 · Reply

EmotionlessMarket Feb. 18 at 3:29 PM

0 · Reply

Estimize Feb. 18 at 2:18 PM

Wall St is expecting 2.14 EPS for $COLL Q4 [Reporting 02/26 BMO] http://www.estimize.com/intro/coll?chart=historical&metric_name=eps&utm_co

0 · Reply

jewell69 Feb. 13 at 3:07 PM

$COLL placed a sell 300 on a mkt on close order 2/13/26 now at 10;06 am est the b a is 45.51 x .60 last trade 45.53 high so far for the day 45.84; 45.28 is the low so for the day as of 10:06 am est

1 · Reply

jewell69 Feb. 11 at 7:36 PM

$COLL 2/10 B 300 44.56 2/11 B 300 44.69 2/11 S 300 45.39 ALL done in an ira. I still own 300 "living in luxury on the pain and suffering of others" they sell non-addictive opiods.

0 · Reply

jewell69 Feb. 11 at 5:36 PM

$COLL doubling down b yesterdday 2/10 300 b 300 more on bad down day -4.58% on ?? good ?? news ?? Truist Adjusts Price Target on Collegium Pharmaceutical to $58 From $55, Maintains Buy Rating

1 · Reply

jewell69 Feb. 10 at 4:11 PM

0 · Reply

jewell69 Feb. 10 at 1:34 AM

0 · Reply

BillionerOfKing Feb. 5 at 5:38 AM

0 · Reply

EMflow Feb. 4 at 1:59 PM

$COLL is a biotech focused on developing small molecule cancer therapies; it is a preclinical/early clinical stage company with a high-risk pipeline.

1 · Reply

hanqex Jan. 24 at 5:15 AM

$COLL I think its a good time to go in to this. This all the technical indicators suggests this is a hidden gem. What are people's thoughts on this?

2 · Reply

Itinerant Jan. 16 at 9:57 PM

$COLL Does anyone have a theory about today's selling? The only thing that I see is that the price broke down through the 50 day moving average. Maybe that was enough for the algo's to sell. The stock is seriously under valued by the mathematics, even if one adds $2 billion of litigation risk. I bought the lows. JMO

1 · Reply

jewell69 Jan. 13 at 1:59 AM

Did everyone see that $BEAM was up 22.5% today 1/12/26 Now, new topic, thinking about $COLL losing -4.5% around Wednesday 1/7/26 Worth a trade if it hasn’t yet regained that dip ditto $BX

0 · Reply

jewell69 Jan. 9 at 6:34 PM

$COLL s 39. 46.04 around 22:50 pm 1/9 Day trade 4 small profit

0 · Reply

jewell69 Jan. 9 at 4:18 PM

$COLL re-entry (sticker shock ) 01/09/2026 Buy Trade Details COLL COLLEGIUM PHARMACEUTICAL 40 $45.29 -$1,811.60 10/03/2025 Sell Trade Details COLL COLLEGIUM PHARMACEUTICAL 200 $34.70 $0.03 $6,939.97 10/02/2025 Buy Trade Details COLL COLLEGIUM PHARMACEUTICAL 200 $34.30 -$6,860.00

0 · Reply

jewell69 Jan. 9 at 3:58 PM

$COLL I used to joke "got opium" because they sell pain medicine. ok, trying to buy, it is still up tons despite being down -6.3% today 1/9/26 Buy 40 COLL @ Limit $45.29, Day Estimated amount $1,811.60 Estimated commission $0.00 Estimated industry fee $0.00 Estimated total amount $1,811.60

0 · Reply

jewell69 Jan. 9 at 3:54 PM

$COLL Truist raised the firm’s price target on Collegium Pharmaceutical (COLL) to $55 from $47 and keeps a Buy rating on the shares. The affordable medicines theme remains attractive heading into 2026, the analyst tells investors in a research note.

0 · Reply

jewell69 Jan. 9 at 3:50 PM

$COLL JORNAY PM = their ADHD drug "The outstanding performance of Jornay PM, along with sustained revenue growth across our pain portfolio, has put us in a strong financial position as we enter the year ahead."Co is on track to achieve recently increased financial guidance for 2025 and expects additional topline revenue growth in 2026 to be driven largely by increasing Jornay PM sales.

0 · Reply

jewell69 Jan. 9 at 3:47 PM

$COLL -6.95% this morning 1/9/26 COMPARE TO +6% ON 12/24/25 Barclays cuts target price to $56 from $58 * Collegium Pharmaceutical Inc : H.C. Wainwright ups target price to $60 from $46 * Collegium Pharmaceutical Inc : Needham raises target price to $56 from $48 *

0 · Reply

Stefan100 Dec. 30 at 2:28 PM

$COLL refinancing of term loan. Lowering rate by 175bps to SOFR + 2.75%. On around $600MM that’s 11mm or so. Very million helps… https://ir.collegiumpharma.com/news-releases/news-release-details/collegium-announces-closing-980-million-syndicated-credit

1 · Reply

jewell69 Dec. 25 at 1:17 AM

$COLL did everybody see it was up 6.5% today 12/24/25

2 · Reply

Market Cap	1.42B
Revenue (ttm)	631.45M
Net Income (ttm)	69.19M
EPS (ttm)	N/A
PE Ratio	7.07
Forward PE	6.84
Profit Margin	10.96%
Debt to Equity Ratio	2.07

Volume	154,285
Avg Vol	444,256
Day's Range	N/A - N/A
Shares Out	31.61M
Stochastic %K	29%
Beta	0.64
Analysts	Strong Sell
Price Target	$53.67